Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase

Nature Medicine

Volumn 3, Issue 6, 1997, Pages 665-670

  Grob, Peter M ^a   Cao, Yunzhen ^b   Muchmore, Elizabeth ^c   David, D H O ^b   Norris, Steve ^a   Pav, Joseph W ^a   Shih, Cheng Kon ^a   Adams, Julian ^d  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Lab Exp Med and Surg in Primates   (United States)

^d ProScript Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMPANZEE; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; SEROCONVERSION; VERTICAL TRANSMISSION; VIREMIA;

ANIMALS; ANTI-HIV AGENTS; DNA, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; LEUKOCYTES, MONONUCLEAR; NEVIRAPINE; PAN TROGLODYTES; PHYTOHEMAGGLUTININS; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TETANUS TOXOID; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS;

EID: 0030990532     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0697-665     Document Type: Article

References (17)

1. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
2. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
3. Mellors, J.W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170 (1996).
4. Connor, E.M. et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331, 1173-1180 (1994).
5. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
6. Merluzzi, V.J. et al. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 250, 1411 -1413 (1990).
7. Koup, R.A. et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-S87. J. Infect. Dis. 163, 966-970 (1991).
8. D'Aquila, R.T. et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 124, 1019-1030 (1996).
9. Murphy, R.L. & Montaner, J. Nevirapine: A review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Invest. Drugs 5, 1183-1199 (1996).
10. Chessman, S.H. et al. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37, 178-182 (1993).
11. Johnson, B.K. et al. Long-term observations of human immunodeficiency virus-infected chimpanzees. Aids Res. Hum. Retroviruses 9, 375-778 (1993).
12. + lymphocytopenia and thrombocytopenia in a chimpanzee persistently infected with a human immunodeficiency virus type 1. J. Infect. Dis. 163, 441-447 (1991).
13. Girard, M. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 542-546 (1991).
14. Girard, M. et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69, 6239-6248 (1995).
15. Berman, P.W. et al. Protection of MN-rgp 120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173, 52-59 (1996).
16. Prince, A.M. et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. Aids Res. Hum. Retroviruses 7, 971-973 (1991).
17. n:8 infection in chimpanzees by CD4 immunoadhesin. Nature 352, 434-436 (1991).